31180 Federal Register / Vol. 65, No. 95 / Tuesday, May 16, 2000 / Notices

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. OMB has now approved the

information collection and has assigned

OMB control number 0910–0186. The

approval expires on April 30, 2003. A

copy of the supporting statement for this

information collection is available on

the Internet at http://www.fda.gov/

ohrms/dockets.

Dated: May 9, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 00–12179 Filed 5–15–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Science Advisory Board to the

National Center for Toxicological

Research Advisory Committee; Notice

of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: Science

Advisory Board (the Board) to the

National Center for Toxicological

Research (NCTR).

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on June 5, 2000, 1 p.m. to 4:30

p.m., and June 6, 2000, 8:30 a.m. to 1

p.m.

Location: NCTR, Bldg. #12,

Conference Center, Jefferson, AR.

Contact Person: Ronald F. Coene,

NCTR (HFT–10), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–6696, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12559. Please call the Information Line

for up-to-date information on this

meeting.

Agenda: The Board will be presented

with draft reports on evaluations of

NCTR’s research programs in Endocrine

Disrupter Knowledge Base, and

Microbiology, for their review,

discussion, and approval. The draft

reports are the products of two site visit

teams who conducted on site reviews

over the last year. The staff from these

programs will provide a preliminary

response to the issues raised and

recommendations made. Three progress

reports will be presented to the Board

on the recommendations it made at its

last meeting, as a result of earlier site

visits, on NCTR’s programs in BioChem

Toxicology, Genetic Toxicology and

Molecular Epidemiology. The NCTR

Acting Director will also provide a

Center update and a discussion of future

research directions.

Procedure: On June 5, 2000, from 1

p.m. to 4:30 p.m., and June 6, 2000,

from 8:30 a.m. to 12 noon, the meeting

is open to the public. Interested persons

may present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by May 23, 2000. Oral

presentations from the public will be

scheduled between approximately 11

a.m. and 12 noon on June 6, 2000. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before May 23, 2000, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

requested to make their presentation.

Closed Committee Deliberations: On

June 6, 2000, from 12 noon to 1 p.m.,

the meeting will be closed to permit

discussion where disclosure would

constitute a clearly unwarranted

invasion of personal privacy (5 U.S.C.

552b(c)(6)). This portion of the meeting

will be closed to permit discussion of

information concerning individuals

associated with the research programs at

NCTR.

The Commissioner of Food and Drugs

approves the scheduling of meetings at

locations outside the Washington, DC

area on the basis of the criteria of 21

CFR 14.22 of FDA’s regulations relating

to public advisory committees.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 5, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–12180 Filed 5–15–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Fiscal Year (FY) 2000 Funding

Opportunities

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice of Funding Availability.

SUMMARY: The Substance Abuse and

Mental Health Services Administration

(SAMHSA) Center for Substance Abuse

Treatment (CSAT) announces the

availability of FY 2000 funds for grants

for the following activity. This activity

is discussed in more detail under

Section 3 of this notice. This notice is

not a complete description of the

activity; potential applicants must

obtain a copy of the Program

Announcement, including Part I,

Programmatic Guidance for Grants to

Expand Substance Abuse Treatment

Capacity in Targeted Areas of Need, and

Part II, General Policies and Procedures

Applicable to all SAMHSA Applications

for Discretionary Grants and

Cooperative Agreements, before

preparing an application.

Activity Application deadline Est. funds FY 2000 Est. No. of awards

Cooperative Agreement for a National Center for

Mentally Ill and Substance Abusing Youth and

Adults Involved with the Justice System.

July 21, 2000 ................. Up to $1,200,000 ........... 1 Up to 3 years.

The actual amount available for

awards and their allocation may vary,

depending on unanticipated program

requirements and the number and

quality of applications received. FY

2000 funds for the activity discussed in

this announcement were appropriated

by the Congress under Public Law No.

106–113. SAMHSA’s policies and

procedures for peer review and

Advisory Council review of grant and

cooperative agreement applications

were published in the Federal Register

(Vol. 58, No. 126) on July 2, 1993.